Illumina Stock Dips Late Despite Second-Quarter Beat And Raise

Illumina stock dipped late Thursday after the genetic testing company reported adjusted profit of $1.87 per share on $1.13 billion in second-quarter sales.


On average, analysts polled by FactSet expected Illumina (ILMN) earnings of $1.36 per share and $1.01 billion in sales.

In the year-earlier period, Illumina earned 62 cents a share on $633 million in sales.

For the year, Illumina predicts adjusted profit of $6.30-$6.50 a share and 32%-34% sales growth. Analysts had projected earnings of $6 per share and $4.16 billion in sales.

In after-hours trading on the stock market today, Illumina stock dipped a fraction near 515. During the regular session, shares ticked up into a buy zone above a buy point at 488.10 out of a cup-with-handle base on the weekly chart, according to

More to follow.

Follow Allison Gatlin on Twitter at @IBD_AGatlin.


Moderna Stock, IBD 50 Stock To Watch, Notches New Record As Earnings Obliterate Forecasts

Regeneron Stock Flirts With Breakout As Covid Drug Beats Views By $1 Billion

Short-Term Trades Can Add Up To Big Profits. IBD’s SwingTrader Shows You How

Want More IBD Insights? Subscribe To Our Investing Podcast!

Find Today’s Best Growth Stocks To Watch With IBD 50

Most Related Links :
reporterwings Governmental News Finance News

Source link

Back to top button